Search
Efavirenz
go.drugbank.com/drugs/DB00625ApprovedInvestigationalEfavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human … Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a
Synonyms: (S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, 6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-oneFenproporex
go.drugbank.com/drugs/DB01550ApprovedIllicitWithdrawnIn 2006 and 2009, the FDA issued warnings that it had been detected in diet pills sold online, and imported from foreign manufacturers. … It is used as an appetite suppressant and a treatment for obesity.
Products: IFA-DIETY A. P.Capmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigationalManufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020,[L13380] for the treatment of NSCLC in patients whose tumors have … day.
Brincidofovir
go.drugbank.com/drugs/DB12151ApprovedInvestigationalBrincidofovir, developed by Chimerix under the brand name Tembexa, was approved by the FDA for the treatment of smallpox infection in June 2021. … [A235725,A235735] Due to its formulation as a pro-drug brincidofovir also carries a greater bioavailability than cidofovir,[A235740,A235725] allowing for oral administration rather than intravenous.
Categories: Cytomegalovirus Nucleoside Analog DNA Polymerase InhibitorSibutramine
go.drugbank.com/drugs/DB01105ApprovedIllicitWithdrawnSibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. … It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States.
Trastuzumab
go.drugbank.com/drugs/DB00072ApprovedInvestigationalIn November 2023, trastuzumab was also approved by the EMA under the brand name Herwenda.[L49339] … Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody [A40276] that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular
Cariprazine
go.drugbank.com/drugs/DB06016ApprovedInvestigational[A247100] It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. … Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary.
Categories: Dopamine D2/D3 receptor modulatorsDaridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigationalConventional treatments for insomnia include drugs targeting gamma-aminobutyric acid type-A (GABA-A), serotonin, histamine, or melatonin receptors; however, undesirable side effects are frequently reported … Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia.
Grazoprevir
go.drugbank.com/drugs/DB11575ApprovedGrazoprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. … in the NS5A protein and previous treatment failure with [DB00811], [DB00008], [DB00022], or other NS3/4A inhibitors like [DB08873], [DB06290], or [DB05521] [FDA Label].
Categories: NS3/4A Protease Inhibitors, HCV NS3/4A Protease InhibitorsLovotibeglogene autotemcel
go.drugbank.com/drugs/DB18680ApprovedInvestigational[A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who … have a history of vaso-occlusive events.